Ribociclib’s mechanism of action

Ribociclib is reported to be one of the most selective CDK4/6 inhibitors and has dose-dependent anti-tumor activity in many preclinical models. It inhibits tumor cell growth by blocking cells at the G1 checkpoint, thereby preventing tumor cell proliferation. Inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6) may provide protection against oncogenic processes in specific tissue types. For example, based on studies in knockout mice, CDK4 is not required for normal mammary tissue development but is required for Ras-induced mammary tumor growth, suggesting a potential therapeutic window for less toxic treatments.